Skip to content
Home/Companies/Biotech/Dorian Therapeutics

Dorian Therapeutics

Biotech·United States·Exited 2025·Held 2yr
Entry
2023
Hold
2yr
Exit
2025

Who owns Dorian Therapeutics?

Dorian Therapeutics was owned by Vento through Vento Fund I (2022 vintage) from 2023 to 2025, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-02

Vento
Investor
Vento
Vento Fund I · 2022 · VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2025

More from Vento Fund I

Other portfolio companies in the same fund.

Allelica
Allelica
Active
HealthTechItaly· 2024
Anthropos
Anthropos
Active
HR TechUnited States· 2024
Arke
Arke
Active
SoftwareItaly· 2024
Bee AI
Exited 2025
AI/MLUnited States· 2024
to
Bland (Bland AI)
Bland (Bland AI)
Active
AI/MLUnited States· 2024
Cariqa
Cariqa
Active
MobilityGermany· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Dorian Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Dorian Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue